Something afoot ?, page-21

First 21 Last

Share
Profile

Follow
LU3434

110 Posts.

1

20/05/18

03:17

Post #: 33213307
Share

Originally posted by DavieJones ↑

I think that some opportunistic investors (including myself) are looking for ;

- a last minute sweetener next week by Merck to ensure that they get a "yes" vote, or
- potentially a disruptive superior offer (from a Chinese pharma ?) a la Sirtex. Given that Merck's in the driving seat with the option to match any competitive offer, a serious potential bidder would wait until the last moment to submit an offer in order to get the shareholder meeting postponed or force a "no" vote. In this case, the bidding process could continue on a level playing field after the dust settles. There's no point in going in early as it would give Merck time to get the internal approval to match the offer.

With regards to the competition, IDO inhibitor combos were expected to be the next generation of immunotherapy treatments but these have bombed with all late stage trials having ceased prematurely. The Nektar/BMS combo deal (worth up to US $3.6B) looks like it isn't performing as well as previously expected.... pls see following.
Www.endpts.com/the-top-winners-and-losers-on-asco-abstract-night-loxo-blueprint-jounce-merck-kgaa-and-more/

All IMHO. Obviously, I'm still hopeful.
GLTAH

Expand

Thanks DJ - I would be surprised if Merck was going to sweeten the deal, however am still hopeful of a last minute counter. Still would have thought BMS would be keen.
The wait will be over soon, certainly not going to sell now, after over a decade of patiently waiting...
Good luck

VLA Price at posting: $1.74 Sentiment: Hold Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

IRE

Iress runs 'hot' for Wealth Within's stock tips

Failure to report prompts ASX to impose multiple company suspensions

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals